Home Health B.C. study finds low but increased risk of myocarditis after 2nd Moderna COVID shot

B.C. study finds low but increased risk of myocarditis after 2nd Moderna COVID shot

by News Desk
0 comment

A Canadian study found that cases of myocardial inflammation associated with the COVID-19 mRNA vaccine were rare, but were more likely to occur in young people who received a second dose of Moderna compared to those who received Pfizer-BioNTech’s vaccine. suggested to be higher than expected.

A Canadian study found that cases of myocardial inflammation associated with the COVID-19 mRNA vaccine were rare, but were more likely to occur in young people who received a second dose of Moderna compared to those who received Pfizer-BioNTech’s vaccine. suggested to be higher than expected.

Lead author Dr. Naveed Janjua, an epidemiologist at the BC Centers for Disease Control, said the findings on the second dose of both vaccines showed that men aged 18 to 29 who received Moderna’s COVID-19 vaccine showed the highest risk of myocarditis. .

He said the study was based on the number of hospitalizations, emergency room visits, It said it would strengthen previous studies elsewhere with more robust data based on lab tests.

The study, published this week in the Journal of the Canadian Medical Association, used data to determine whether people sought treatment for myocarditis 7 and 21 days after vaccination.

Pfizer received approximately 7 million doses and Moderna 3.2 million doses. Nearly 4 million first doses, 3.8 million second doses, and nearly 2.4 million third doses.

Researchers identified 99 cases of myocarditis out of a total of 10.2 million doses given. They expected to see about seven cases, mostly women, based on typicality. Instead, 80 men in the study developed myocarditis, Nineteen women were shown to have developed myocarditis.

Most cases were men and were seen after the second dose. On average, men were younger than women, with cases within 7 days making him 28 vs 45, and cases within 21 days making him 31 vs 49.

After two doses of 100,000 doses of Moderna in men aged 18 to 29, 22 cases of myocarditis were found. This compares with his 5 cases per 100,000 men in that age group who received her second dose of Pfizer’s vaccine.

However, seven days after the third dose of Moderna, the findings showed that there were 4 cases of heart disease per 100,000 doses in that age group, compared with 3 cases per 100,000 doses with Pfizer Booster. indicates that

Myocarditis cases are usually mild for young men who seek medical help because of chest pain after vaccination, Janjua said.

“When I say mild, I mean self-resolving. So these were people who had been sick for a day, two or three days and then recovered. By comparison,[the condition]remained very long, and I was hospitalized for 10 to 12 days.”

Symptoms include chest pain, shortness of breath, and rapid or abnormal heart rhythm.

Myocarditis can occur for a variety of reasons, including viral infections like influenza, and is usually seen in older people.

“Given the mild nature of the disease, we don’t think there will be any sequelae,” Janjua said of the myocarditis involving a young man who received the mRNA vaccine, who would otherwise be less likely to get sick. rice field.

Based on their findings, the study’s authors say they support using Pfizer for a second shot in men between the ages of 18 and 29. This follows a National Immunization Advisory Board recommendation last December for those aged 12 to her 29, Pfizer is better suited for her first and her second doses than Moderna. I agree with what you said.

In a statement, the NACI said people aged 18 to 29 “may prefer” Pfizer.

Earlier this month, the FDA said there was currently no evidence to suggest meaningful differences in protection between the original COVID-19 strain and different bivalent booster vaccines targeting the Omicron subvariant, stating that “Moderna (50 mcg) and A bivalent booster product from Pfizer-BioNTech (30 mcg).”

The authors of a study based in British Columbia found little difference in myocarditis incidence after the third dose of Moderna and Pfizer BioNtech.

Janjua, who is also a clinical professor in the Department of Population and Public Health at the University of British Columbia, said it may be because Moderna cut the booster shot dosage in half to 50 micrograms.

“Moderna responded better than Pfizer,” Yangjua said of the first dose. “But of course, at higher doses, you might see some of these complications, such as myocarditis.

Moderna did not respond to requests for comment on the study or the risk of myocarditis from the second dose.

Since 2021, there have been international reports of post-COVID-19 vaccination cases associated with myocarditis and pericarditis (inflammation of the two-layered sac that surrounds the heart) among young men aged 12 years, with progressing research is encouraged.

A study published in the Journal of the American Medical Association in January, along with studies including those from the US Centers for Disease Control and Prevention, were based on data seven days after the second dose of the mRNA vaccine.

Among men aged 18 to 24 years, 56 cases per million doses after Moderna vaccination were reported, compared with 52 cases per million doses for men who received the second Pfizer injection. it was done.

Janjua said other researchers are trying to figure out why men have a higher risk of myocarditis associated with the COVID-19 mRNA vaccine compared to women, but hormonal differences related to immunity may be a factor. It is believed that

Although most cases are mild and resolved quickly, the National Advisory Board on Immunization last December strongly recommended that people aged 12 to 29 receive the Pfizer vaccine.

Overall, Janjua said the risk of complications from COVID-19 infection is far higher than the risk of developing myocarditis from the Moderna vaccine, and advises if there are no other options.

“Use whatever is available to reduce the risk of infection.”

This report by the Canadian Press was first published on November 23, 2022.

This article was produced with financial support from the Canadian Medical Association.

Camille Baines, Canadian Press

You may also like

Leave a Comment

Copyright ©️ All rights reserved. | Canadian Trends